BioXcel Therapeutics, Inc.
BTAIQ
$0.05
$0.009.56%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 742.00K | 680.00K | 642.00K | 752.00K | 868.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 742.00K | 680.00K | 642.00K | 752.00K | 868.00K |
| Cost of Revenue | 348.00K | 433.00K | 164.00K | 964.00K | 2.12M |
| Gross Profit | 394.00K | 247.00K | 478.00K | -212.00K | -1.26M |
| SG&A Expenses | 23.57M | 21.99M | 20.49M | 20.78M | 23.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.47M | 51.07M | 50.91M | 51.20M | 51.02M |
| Operating Income | -44.73M | -50.39M | -50.27M | -50.45M | -50.15M |
| Income Before Tax | -70.86M | -75.33M | -69.90M | -68.21M | -50.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -70.86 | -75.33 | -69.90 | -68.21 | -50.95 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.86M | -75.33M | -69.90M | -68.21M | -50.95M |
| EBIT | -44.73M | -50.39M | -50.27M | -50.45M | -50.15M |
| EBITDA | -44.51M | -50.11M | -49.97M | -50.14M | -49.85M |
| EPS Basic | -3.78 | -5.74 | -6.70 | -9.70 | -12.67 |
| Normalized Basic EPS | -2.35 | -3.58 | -4.18 | -6.05 | -7.55 |
| EPS Diluted | -3.78 | -5.74 | -6.70 | -9.70 | -12.67 |
| Normalized Diluted EPS | -2.35 | -3.58 | -4.18 | -6.05 | -7.55 |
| Average Basic Shares Outstanding | 89.92M | 67.47M | 48.73M | 29.91M | 18.37M |
| Average Diluted Shares Outstanding | 89.92M | 67.47M | 48.73M | 29.91M | 18.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |